Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
ABSTRACT: Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the vaccination strategy. This study assessed the persistence of neut...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/da37d3d71f2c4e7c991588715ee89918 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:da37d3d71f2c4e7c991588715ee89918 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:da37d3d71f2c4e7c991588715ee899182021-11-30T04:14:04ZNeutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients1201-971210.1016/j.ijid.2021.09.002https://doaj.org/article/da37d3d71f2c4e7c991588715ee899182021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007074https://doaj.org/toc/1201-9712ABSTRACT: Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the vaccination strategy. This study assessed the persistence of neutralizing antibody (Nab) activity and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients 9 months post symptom onset (PSO) in a primary care context among immunocompetent adults. Methods: A longitudinal cohort of crew members (CMs) exposed to coronavirus disease 2019 (COVID-19) during an outbreak of SARS-CoV-2 on the French aircraft carrier ‘Charles de Gaulle’ in April 2020 was created. CMs infected with COVID-19 and with positive serology at the end of quarantine were tested 9 months PSO. Samples were collected 18 and 280 days PSO. For each patient, both serology and serum viral neutralizing activity were performed. Results: In total, 86 CMs were analysed. Samples were collected 18 and 280 days PSO. The seroconversion rates were 100% and 93% (82/86) at 18 and 280 days PSO, respectively, and 72.7% of patients exhibited persistent Nab activity at 9 months, regardless of disease severity. Conclusion: Nab activity persists for up to 9 months following asymptomatic/mild COVID-19 among young adults, regardless of serological results.Olivier BylickiDavid DelarbreAurélie MayetAudrey FerrierAnne PerisseCarine MalleJacques CobolaAntoine BronsteinNastasia MenoudElodie Valero-BianceOlivier FerrarisFrédéric JanvierJean-Nicolas TournierElsevierarticleSARS-CoV-2 infectionNeutralizing antibodiesOutbreakSerologyInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 112, Iss , Pp 8-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
SARS-CoV-2 infection Neutralizing antibodies Outbreak Serology Infectious and parasitic diseases RC109-216 |
| spellingShingle |
SARS-CoV-2 infection Neutralizing antibodies Outbreak Serology Infectious and parasitic diseases RC109-216 Olivier Bylicki David Delarbre Aurélie Mayet Audrey Ferrier Anne Perisse Carine Malle Jacques Cobola Antoine Bronstein Nastasia Menoud Elodie Valero-Biance Olivier Ferraris Frédéric Janvier Jean-Nicolas Tournier Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| description |
ABSTRACT: Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the vaccination strategy. This study assessed the persistence of neutralizing antibody (Nab) activity and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients 9 months post symptom onset (PSO) in a primary care context among immunocompetent adults. Methods: A longitudinal cohort of crew members (CMs) exposed to coronavirus disease 2019 (COVID-19) during an outbreak of SARS-CoV-2 on the French aircraft carrier ‘Charles de Gaulle’ in April 2020 was created. CMs infected with COVID-19 and with positive serology at the end of quarantine were tested 9 months PSO. Samples were collected 18 and 280 days PSO. For each patient, both serology and serum viral neutralizing activity were performed. Results: In total, 86 CMs were analysed. Samples were collected 18 and 280 days PSO. The seroconversion rates were 100% and 93% (82/86) at 18 and 280 days PSO, respectively, and 72.7% of patients exhibited persistent Nab activity at 9 months, regardless of disease severity. Conclusion: Nab activity persists for up to 9 months following asymptomatic/mild COVID-19 among young adults, regardless of serological results. |
| format |
article |
| author |
Olivier Bylicki David Delarbre Aurélie Mayet Audrey Ferrier Anne Perisse Carine Malle Jacques Cobola Antoine Bronstein Nastasia Menoud Elodie Valero-Biance Olivier Ferraris Frédéric Janvier Jean-Nicolas Tournier |
| author_facet |
Olivier Bylicki David Delarbre Aurélie Mayet Audrey Ferrier Anne Perisse Carine Malle Jacques Cobola Antoine Bronstein Nastasia Menoud Elodie Valero-Biance Olivier Ferraris Frédéric Janvier Jean-Nicolas Tournier |
| author_sort |
Olivier Bylicki |
| title |
Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| title_short |
Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| title_full |
Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| title_fullStr |
Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| title_full_unstemmed |
Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| title_sort |
neutralizing antibody response to sars-cov-2 persists 9 months post symptom onset in mild and asymptomatic patients |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/da37d3d71f2c4e7c991588715ee89918 |
| work_keys_str_mv |
AT olivierbylicki neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT daviddelarbre neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT aureliemayet neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT audreyferrier neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT anneperisse neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT carinemalle neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT jacquescobola neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT antoinebronstein neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT nastasiamenoud neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT elodievalerobiance neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT olivierferraris neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT fredericjanvier neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients AT jeannicolastournier neutralizingantibodyresponsetosarscov2persists9monthspostsymptomonsetinmildandasymptomaticpatients |
| _version_ |
1718406833303977984 |